Solventum (SOLV) fundamentals: P/E, valuation, undervalued?
Solventum · Health Care · ref. ETF XLV · price $90.93
In short — Solventum trades at 11.2× earnings (P/E), 12.6× forward, with a net margin of 17.3 % and revenue growth of +2 %. Read: Low P/E (P/E 11 (below the ~20 market average)).
Is Solventum stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$90.93+25.1% over range
Aug 28, 25low $62.49 · high $91.61Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
67% recommend buying · 9 analysts
Valuation : Low P/E — P/E 11 (below the ~20 market average)
Valuation
11.2
P/E (price/earnings)
12.6
Forward P/E
2.87
PEG
3.2
Price/book (P/B)
$15.5B
Market cap
8.13
EPS
Profitability & growth
17.3 %
Net margin
+2 %
Revenue growth
+4 %
Earnings growth
$5.3B
Total debt
Solventum income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $0 | $1.3B | — |
| 2024 | $8.3B | $479M | 5.8 % |
| 2025 | $8.3B | $1.6B | 18.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Solventum's P/E and is the stock undervalued? What's a good P/E?
Solventum's P/E is 11.2 (forward 12.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Low P/E".
Is Solventum profitable?
Solventum has a net margin of 17.3 % (EPS 8.13). The company is profitable.
Is SOLV stock expensive?
Our read: "Low P/E" — P/E 11 (below the ~20 market average). Cross-check with growth and sector.
💬 A question about Solventum? The JPI assistant answers using our backtest data.
Keep exploring Solventum